Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
about
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolAcute lymphoblastic leukaemiaCurrent Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceMercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fictionChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationMLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study.Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology GroupGene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.Genomic inverse PCR for exploration of ligated breakpoints (GIPFEL), a new method to detect translocations in leukemiaCranial radiation for pediatric T-lineage acute lymphoblastic leukemia: a systematic review and meta-analysis.Low PKCĪ± expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome.Early Response to Dexamethasone as Prognostic Factor: Result from Indonesian Childhood WK-ALL Protocol in YogyakartaA revised definition for cure of childhood acute lymphoblastic leukemia.Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual diseaseEfficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.Outcomes after induction failure in childhood acute lymphoblastic leukemia.End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia.Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemiaPediatric acute lymphoblastic leukemia: where are we going and how do we get there?Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyTransplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicityTime point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment StrategiesDeep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.Measurements of treatment response in childhood acute leukemia.Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary TherapyHematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry.Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia
P2860
Q23749304-B67582CD-9859-46C7-8F72-3508BEC4014DQ24602387-E3B02AFD-B2C3-40DB-81AD-967630324AAEQ26751269-CAB5DF5C-173C-42F3-B840-EE7631A1B43FQ26828511-322654ED-A1BA-43AA-84CC-6CE1E52A2D2CQ26866517-60CC8AA7-BC68-4177-AB7F-9EA13A01772EQ27023839-4F93AE24-5651-4DB0-9132-27210137DABEQ28087637-2C43A989-926B-4E1B-B487-2F7F6BFD3E57Q30277191-95A379EF-1E7D-4035-A51F-2160E7998AA4Q30300395-8CBB380A-722F-488A-AC21-A81A80BC3352Q30417943-10753A4B-260B-43E7-981E-BDC301D6C770Q33413888-AA32F4AA-A730-47CD-B7F8-33F902FF5440Q33770150-A9690D47-3A8F-4771-AD35-9D07B996CD04Q34066349-173A1176-9B67-4F67-8353-FB20F1152234Q34203403-8BCEE720-C27E-42E2-97BC-8496E066776EQ34221792-2D9DE7E8-92AD-47F9-9866-8F1555A58CB0Q34252624-83F2E3E3-ED10-4914-BFB8-771B01E55DD3Q34429332-2586E187-F8C8-4F35-97DD-94F7401E3DBFQ34490429-D6F79883-4EFE-47C5-ABEA-02132F4634F2Q35022780-BD4807B2-A9B8-4562-A665-0BB6ED723BD3Q35171267-0099CB92-959D-4F5E-95BB-757E458769DEQ35437903-71539920-68B7-4D9C-BDC7-F096530EBC88Q35690710-EB08A69E-A778-4B8B-BA01-E93680270D34Q35853569-519DCC0F-1CFA-4FE0-B097-4764888AD9FAQ36029619-46AED321-762F-4BA1-991F-2D4E99274D68Q36093798-A179A993-4F5A-4D89-8D59-74DD41B6BD6AQ36094717-EC69F84B-515E-4443-8610-4A397AEA4388Q36163029-E2960149-F12B-4CF1-BBD2-4F9B48D3DD8CQ36182008-A3982B84-3305-4AB6-8805-CE27690013F2Q36201257-637F87FA-876B-46C2-AFCB-986A1C6BDBAEQ36302281-4A28D744-4477-4D3D-A310-F4B8688FD6C5Q36317718-E25004A1-BE0D-43C2-BC44-35267DBA1703Q36366977-743680BE-A3FC-4573-94FE-C40EAEDEC24EQ36469789-8F8ED340-FC5A-41A1-849A-378AA4212E6AQ36509641-963FB2BD-AE1C-440B-8BBE-935F1089D29BQ36513773-E9AE9A7C-65E3-4368-9317-604FAD18297DQ36731636-EB1B835C-F54D-4E8F-9DA7-88240AFFC9A6Q36892602-58587173-EC60-490A-907B-3D6B4CF79C4DQ36914357-CF1F3D3F-ED8C-4391-9EBC-B4DB530976C3Q37060668-129B8D9A-A314-447F-9318-AABAF86EE6A0Q37148110-A4E2D71E-9876-453B-A327-3466875ADF00
P2860
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
description
2011 nĆ® lÅ«n-bĆ»n
@nan
2011幓ć®č«ę
@ja
2011幓å¦ęÆęē«
@wuu
2011幓å¦ęÆęē«
@zh-cn
2011幓å¦ęÆęē«
@zh-hans
2011幓å¦ęÆęē«
@zh-my
2011幓å¦ęÆęē«
@zh-sg
2011幓åøč”ęē«
@yue
2011幓åøč”ęē«
@zh
2011幓åøč”ęē«
@zh-hant
name
Late MRD response determines r ...... the AIEOP-BFM-ALL 2000 study.
@en
Late MRD response determines r ...... the AIEOP-BFM-ALL 2000 study.
@nl
type
label
Late MRD response determines r ...... the AIEOP-BFM-ALL 2000 study.
@en
Late MRD response determines r ...... the AIEOP-BFM-ALL 2000 study.
@nl
prefLabel
Late MRD response determines r ...... the AIEOP-BFM-ALL 2000 study.
@en
Late MRD response determines r ...... the AIEOP-BFM-ALL 2000 study.
@nl
P2093
P50
P1433
P1476
Late MRD response determines r ...... the AIEOP-BFM-ALL 2000 study.
@en
P2093
Alfred Reiter
Andrea Biondi
AndrƩ Schrauder
Anja Mƶricke
Barbara Buldini
Beat W SchƤfer
Chiara Messina
Claus R Bartram
Giovanni Cazzaniga
Giuseppe Basso
P304
P356
10.1182/BLOOD-2011-03-338707
P407
P577
2011-06-30T00:00:00Z